Our results from the combinatorial studies of NextA and anti-PD-1 blocking antibody clearly demonstrate an improvement in the reduction of tumor size and survival, which was associated with a reduction in the expression of several immunosuppressive mediators in tumors, both of which fully support our initial hypothesis. This evidence concerns the gene PDCD1 and neoplasm.